ENXTPA:ALCLSBiotechs
Cellectis (ENXTPA:ALCLS) Q4 EPS Loss Reinforces Bearish Earnings Narratives
Cellectis (ENXTPA:ALCLS) has just posted its FY 2025 results, with Q4 revenue of US$12.2 million, basic EPS of a US$0.26 loss, and trailing twelve month revenue of US$79.6 million alongside a trailing EPS loss of US$0.67. Over recent quarters the company has seen revenue move between US$12.0 million and US$37.2 million per quarter, while quarterly EPS has ranged from a small profit of US$0.01 to a loss of US$0.26. This context may help investors consider how these results fit into the...